Ensysce Biosciences, Inc. (ENSC) Income Statement
ENSC 2025 at a glance
Fiscal year ended December 31, 2025 · U.S. dollarsENSC revenue and net income
Where ENSC's revenue goes
2025Each bar shows an amount and its share of revenue. ENSC kept −200.8% of revenue as net income.
ENSC profit margins
ENSC growth rates
to 2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | −2.8% | +26.2% | +5.2% | — |
| Gross profit | — | — | — | — |
| Operating income | — | — | — | — |
| Net income | — | — | — | — |
| EPS (diluted) | — | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
ENSC quarterly EPS vs estimates
Ensysce Biosciences beat the analyst EPS estimate in 6 of the last 8 quarters. Next report: November 13, 2026 (estimate $-0.19).
ENSC income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $5.1M | $5.2M | $2.2M | $2.5M | $3.5M | $3.9M | $1.8M | $0 | $0 |
| Cost of revenue | $10.4M | $7.2M | $7.6M | $19.8M | $151 | $201 | $3.3M | $1.6M | — |
| Gross profit | −$5.3M | −$2.0M | −$5.4M | −$17.3M | $3.5M | $3.9M | −$3.3M | −$1.6M | — |
| Research & development | $10.4M | $7.2M | $7.6M | $19.8M | $4.7M | $4.4M | $3.4M | — | — |
| Sales, general & admin | $4.9M | $4.7M | $5.4M | $6.9M | $18.7M | $1.2M | $6.9M | — | — |
| Total operating expenses | $10.2M | $6.7M | $10.7M | $24.2M | $19.9M | $1.6M | $3.3M | −$600,005 | $146,695 |
| Operating income | −$10.2M | −$6.7M | −$10.7M | −$24.2M | −$19.9M | −$1.6M | −$3.3M | −$959,240 | −$147,000 |
| Interest income | $18,770 | $1.3M | $353,950 | $109,530 | $622,000 | $939,650 | $4.2M | $3.6M | $119,140 |
| Interest expense | $18,767 | $1.3M | $353,945 | $109,525 | $1.3M | $995,496 | $0 | $0 | $0 |
| Income before taxes | −$10.2M | −$8.0M | −$10.6M | −$24.2M | −$29.1M | −$160,875 | $921,154 | $2.7M | −$27,558 |
| Income taxes | — | — | −$264 | $753,876 | −$151 | $777,851 | −$555,200 | −$553,916 | $3,635 |
| Net income | −$10.2M | −$8.0M | −$10.6M | −$25.0M | −$29.1M | $56,770 | $1.5M | $2.1M | −$31,193 |
| EBITDA | −$10.2M | −$6.7M | −$10.3M | −$24.2M | −$19.9M | −$1.6M | −$3.3M | −$959,240 | −$27,555 |
| EPS (diluted) | −$4.22 | −$13.40 | −$65.27 | −$2085.03 | −$9.52 | $0.67 | $242.80 | −$174.34 | −$0.01 |
| Gross margin | −104.8% | −38.6% | −240.1% | −686.1% | 100.0% | 100.0% | −188.7% | — | — |
| Operating margin | −202.1% | −129.2% | −480.4% | −959.9% | −562.7% | −41.0% | −188.7% | — | — |
| Net margin | −200.8% | −153.3% | −475.7% | −989.2% | −825.4% | 1.4% | 83.7% | — | — |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.2M | $960,999 | $1.9M | $493,104 | $1.4M | $1.3M | $1.3M | $3.4M | $181,797 | $305,722 | $515,032 | $435,380 |
| Cost of revenue | $0 | $6,533 | — | $3.0M | $1.9M | $1.9M | $3.8M | $1.7M | $947,229 | $778,904 | $2.2M | $1.9M |
| Gross profit | $1.2M | $954,466 | — | −$2.5M | −$551,992 | $1.3M | −$2.5M | $1.7M | −$765,432 | −$473,000 | −$1.7M | −$1.5M |
| Research & development | $2.5M | $3.3M | $3.6M | $3.0M | $1.9M | $1.9M | $3.8M | $1.7M | $947,229 | $778,904 | $2.2M | $1.9M |
| Sales, general & admin | $1.3M | $1.2M | $1.1M | $1.3M | $1.2M | $1.4M | $1.1M | $1.1M | $1.2M | $1.4M | $1.4M | $1.2M |
| Total operating expenses | $3.7M | $3.6M | $2.8M | $3.7M | $1.8M | $2.0M | $3.6M | −$644,746 | $2.0M | $1.8M | $3.2M | $2.7M |
| Operating income | −$2.6M | −$3.6M | −$2.8M | −$3.7M | −$1.8M | −$2.0M | −$3.6M | $644,746 | −$2.0M | −$1.8M | −$3.2M | −$2.7M |
| Interest income | — | — | $5,380 | $6,370 | $3,160 | $3,860 | $10,750 | $4,060 | — | — | — | — |
| Interest expense | $320 | $3,923 | $5,382 | $6,369 | $3,160 | $3,856 | $10,753 | $4,062 | $27,563 | $1.2M | $344,799 | $7,649 |
| Income before taxes | −$2.6M | −$3.6M | −$2.8M | −$3.7M | −$1.7M | −$1.9M | −$3.6M | $661,769 | −$2.0M | −$3.1M | −$3.5M | −$2.7M |
| Income taxes | — | — | — | — | — | — | $74 | — | $2 | −$74 | $360,481 | $6,414 |
| Net income | −$2.6M | −$3.6M | −$2.8M | −$3.7M | −$1.7M | −$1.9M | −$3.6M | $661,769 | −$2.0M | −$3.1M | −$3.5M | −$2.7M |
| EBITDA | −$2.6M | −$3.5M | −$2.8M | −$3.7M | −$1.7M | −$1.9M | −$3.6M | $665,832 | −$1.9M | −$1.9M | −$3.2M | −$2.7M |
| EPS (diluted) | −$0.20 | −$0.52 | −$0.75 | −$1.29 | −$0.79 | −$1.39 | −$2.90 | $1.05 | −$3.30 | −$8.25 | −$1.37 | −$13.05 |
| Gross margin | 100.0% | 99.3% | — | −499.2% | −40.2% | 100.0% | −191.7% | 50.5% | −421.0% | −154.7% | −333.5% | −339.8% |
| Operating margin | −221.3% | −370.7% | −147.8% | −758.7% | −127.6% | −149.1% | −274.3% | 18.9% | −1,075.6% | −602.8% | −612.7% | −621.8% |
| Net margin | −220.8% | −370.1% | −147.0% | −756.3% | −126.4% | −147.4% | −273.4% | 19.4% | −1,082.4% | −1,019.4% | −680.2% | −617.8% |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in ENSC's financial statements (latest annual report filed March 30, 2026); data from EODHD. Sales, general & administrative expenses include sales and marketing.
ENSC financial results
In fiscal year 2025 (ended December 31, 2025), Ensysce Biosciences reported revenue of $5.1 million, down 2.8% from the year before. It had a net loss of $10.2 million, a net profit margin of −200.8%. Diluted earnings per share came to −$4.22. Over five years revenue grew at an average rate of 5.2% a year.
See the ENSC stock overview for the latest quote and news, or the ENSC chart for price history and technical indicators.
ENSC income statement FAQ
What is Ensysce Biosciences's annual revenue?
Ensysce Biosciences reported total revenue of $5.1 million for fiscal year 2025, which ended on December 31, 2025. That was down 2.8% from $5.2 million the previous year.
Is Ensysce Biosciences profitable?
No. Ensysce Biosciences reported a net loss of $10.2 million in fiscal 2025, a net profit margin of −200.8%; its operating margin was −202.1%.
What is Ensysce Biosciences's gross margin?
Ensysce Biosciences's gross margin was −104.8% in fiscal 2025: for every $100 of revenue, Ensysce Biosciences kept $-105 after the direct cost of its products and services.
How much does Ensysce Biosciences spend on research and development?
Ensysce Biosciences spent $10.4 million on research and development in fiscal 2025, 204.8% of revenue.
How fast is Ensysce Biosciences growing?
Revenue grew 5.2% a year on average over the last five fiscal years, from $3.9 million to $5.1 million.
What are Ensysce Biosciences's earnings per share?
Ensysce Biosciences earned $-4.22 per diluted share in fiscal 2025, compared with $-13.40 a year earlier.
When will Ensysce Biosciences report its next earnings?
Ensysce Biosciences is expected to report results for the quarter ending September 30, 2026 on November 13, 2026.
When does Ensysce Biosciences's fiscal year end?
Ensysce Biosciences's fiscal year ends in December. The latest annual report covers the year ended December 31, 2025 and was filed on March 30, 2026.